Avia Logo

Products /

OptiCor

OptiCor

Overview


Select which hospital or health system you work at and see a personalized compatibility level.

Avia Summary

o
OptiCor is a solution provided by tenacio. It belongs to multiple categories of digital health solutions including Digital Therapeutics (DTx), Care Plans, Clinical Decision Support, and Clinical Decision Support Systems.
o
Some other resource(s) that may be helpful in learning about OptiCor include: Exploring the Potential of Digital Therapeutics (WEBINAR) and A Buyer’s Guide to Digital Therapeutics

DESCRIPTION

OptiCor, a cutting-edge Clinical Decision Support Software, leads the way in cardiovascular care by seamlessly incorporating the latest 2023 ACC/AHA Guideline for Atrial Fibrillation. With a validated risk prediction algorithm, OptiCor empowers healthcare professionals with individualized stroke risk assessments, navigating away from the conventional CHA2DS2-VASc scoring system. This paradigm shift aligns perfectly with the guideline's emphasis on personalized therapy decisions, resulting in a significant reduction in mortality, stroke, and bleeding compared to standard care. The user-friendly interface and EHR integration of the enhanced version position OptiCor as the exclusive solution for implementing the new guideline, reinforcing its commitment to shaping the future of cardiovascular care through evidence-based precision and innovation.

Read more
AWARDS
edit-media
edit-media
edit-media
EHR integration

Other
Recommended, but not required
Would prefer not to disclose
None provided
Use cases and differentiators

For physicians and patients with cardiovascular diseases, tenacio provides comprehensive risk assessments and treatment recommendations, making it easier to identify optimal CV care, to increase adherence and to reduce events and cost.

GPs, PCPs, Family Physicians, Cardiologists, NPs, PAs

OptiCor is the only Clinical Decision Support which incorporates the 2023 ACC/AHA AF Guideline because it provides precise treatment decisions based on individual stroke risk prediction.

Its focus is on proven outcome improvements and a superior user experience, making it easier and faster for HCPs to identify the optimal treatment for a patient. 

  • Only CDS which supports the new 2023 ACC/AHA AF treatment paradigm
  • Proven outcome benefits and cost savings
  • Superior user experience
  • FDA reviewed, proprietary and validated risk prediction algorithm
Company information

Media


Images

edit-media
OptiCor_one pager.png
Videos

OptiCor video Jan 2023.mp4
Downloads

Reviews


Filter reviews


Overall Score

0 review


Sort by:
Most Recent
Sort by:
Most Recent
Oldest
Most Helpful

Filter reviews


Reviewer’s Rating
5
4
3
2
1

Reviewer’s Role
  • End user
  • Project manager
  • IT / Technical support
  • Executive sponsor
  • Internal consultant
  • Other

Reviewer’s Org Size
  • XL ($5B+ NPR)
  • L ($3-5B NPR)
  • M ($1-3B NPR)
  • S ($0.2-1B NPR)
  • XS (< $0.2B NPR)

Reviewer’s Org EMR compatibility

Reviewer’s Org Type
  • AMC
  • Pediatric Facilities
  • ACO
  • Rural Presence

Looking for reviews on OptiCor?

Submit your work email and we'll notify you when new reviews have been added.

Clients


Filter clients


Type
  • Partner

  • Vendor

  • Health System

  • Other

Explore Related Resources
back to top